IN-DEPTH: The slow motion race for a TB vaccine

IN-DEPTH: The slow motion race for a TB vaccine

In recent months, the world has seen unprecedented investment in new vaccines. Yet, while a COVID-19 vaccine proven to be safe and effective may be less than a year away, a new tuberculosis vaccine might only be ready to be rolled out in a decade, despite a massive head start over COVID-19. Amy Green takes a closer look at the race for a new vaccine for the world’s top infectious disease killer.

Read More

1.3m switched to new ARV, but weight gain is a concern

1.3m switched to new ARV, but weight gain is a concern

Two years after it was announced that the ARV dolutegravir would become part of standard first line HIV treatment in South Africa, it is finally reaching significant numbers of people. But new research about a worrying side-effect, weight gain (particularly in women), has muddied its otherwise stellar reputation.

Read More

COVID-19 Report: Understanding the most important science of the past week

COVID-19 Report: Understanding the most important science of the past week

Many journalists, including us, are finding the quantity of science reports on COVID-19 overwhelming. We introduce a new occasional column to help make sense of the information overload. The aim of this occasional column, which we’re calling COVID-19 Report, will be to alert reporters in South Africa (and anyone else who is interested) to the best and most important science, and also clear up misconceptions. 

Read More